Home/Clear Scientific/Xinhua Li, PhD

XL

Xinhua Li, PhD

EVP, Drug Development

Clear Scientific

Therapeutic Areas

Substance Use Disorder & Overdose Metabolic Disorders Neurodegenerative Diseases

Clear Scientific Pipeline

Drug	Indication	Phase
Overdose Reversal (Methamphetamine/Fentanyl)	Drug Overdose Reversal	Pre-clinical
Metabolic/CNS Dysfunction	Conditions caused by excess harmful metabolites	Pre-clinical

Leadership Team at Clear Scientific

Chief Executive Officer

John Marota, MD, PhD

Medical Director

Chief Financial Officer

Mitch Zakin, PhD

EVP, Innovation

Winston Henderson, JD

General Counsel

View full Clear Scientific profile